| Code | CSB-RA011593MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to GR-2301, targeting interleukin-15 (IL-15), a pleiotropic cytokine that plays critical roles in immune cell development, activation, and homeostasis. IL-15 is essential for the proliferation and survival of natural killer (NK) cells, CD8+ memory T cells, and NKT cells, functioning through a unique trans-presentation mechanism involving the IL-15 receptor alpha chain. Dysregulated IL-15 signaling has been implicated in various autoimmune disorders including rheumatoid arthritis, inflammatory bowel disease, and psoriasis, as well as in certain hematological malignancies and transplant rejection.
GR-2301 represents an investigational therapeutic antibody designed to neutralize IL-15 activity, making this biosimilar a valuable tool for researchers studying IL-15-mediated immune responses and inflammatory pathways. This antibody enables investigation of IL-15 blockade strategies in preclinical disease models and supports mechanistic studies exploring the role of IL-15 in immune regulation, chronic inflammation, and tumor immunology. It serves as an important reagent for laboratories investigating cytokine biology and evaluating potential therapeutic interventions targeting the IL-15 pathway.
There are currently no reviews for this product.